Ignite Creation Date:
2024-05-06 @ 6:40 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05746208
Status:
RECRUITING
Last Update Posted:
2023-12-19
First Post:
2023-02-17
Brief Title:
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
Sponsor:
University of California San Francisco
Organization:
University of California San Francisco
Organization Data
Organization:
University of California San Francisco
Class:
OTHER
Study ID:
22958
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
University of California San Francisco
Lead Sponsor Class:
OTHER
Responsible Party:
Emily Bergsland
Responsible Party Title:
Principal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
University of California San Francisco
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Merck Sharp Dohme LLC | INDUSTRY |